FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 1, 2007, Pages 15-20

  Ghosn, Marwan ^a   Farhat, Fadi ^b   Kattan, Joseph ^a   Younes, Fariha ^a   Moukadem, Walid ^c   Nasr, Fadi ^a   Chahine, Georges ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b Hammoud Hospital   (Lebanon)

^c Haikal Hospital   (Lebanon)

Author keywords

5 FU; First line; FOLFOX 6; Leucovorin; Oxaliplatin; Pancreatic carcinoma

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LYMPHANGITIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PROGNOSIS; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PATIENT SELECTION;

EID: 33846850256     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000235997.18657.a6     Document Type: Article

References (33)

1. Jemal A, Murray T, Ward E, et al. Cancer Statistics, 2005. CA Cancer J Clin. 2006;56:106-130.
2. Cole P, Rodu B, et al. Descriptive epidemiology: Epidemiology of cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA. CANCER: Principles and Practices of Oncology, ed 6. Philadelphia: Lippincott Williams & Wilkins, 2001.
3. Cullinan SA, Moertel C, Wieand HS, et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin and cisplatin. Cancer. 1990;65:2207-2212.
4. Bertheault-Cvitkovic F, Lévi F, Soussan S, et al. Circadian rhythm modulated chemotherapy 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma. Eur J Cancer. 1993;29A:1851-1854.
5. Tajiri H, Yoshimori M, Okazaki N, et al. Phase II study of continuous venous infusion of 5-fluorouracil in advanced pancreatic cancer. Oncology. 1991;48:18-21.
6. Ducreux M, Rougier P, Pignon JP, et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol. 2002;13:1185-1191.
7. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270-3275.
8. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
9. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] (Abstract). Proc Am Soc Clin Oncol. 2005:1.
10. Wils J, Kok T, Wagener DJ, et al. Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer. 1993;29A:203-204.
11. Rougier P, Zarba J, Basile M, et al. Phase II study of cisplatin and 120 hours continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol. 1993;4:333-336.
12. Nicolson M, Webb A, Cunningham D, et al. Cisplatin and protracted venous infusion 5-fluorouracil (CF): good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann Oncol. 1995;6:801-804.
13. Ko AH, Dito E, Schillinger B, et al. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006;24:379-385.
14. Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother. 2005;39:128-135.
15. Levi F, Zidani R, Misset JL. For the International Organization for Cancer Chronotherapy. Randomised multicenter trial of cheonotherapy with oxaliplatin, fluorouacil and folinic acid in metastatic colorectal cancer. Lancet. 1997;350:681-686.
16. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
17. Kormann M, Kakler H, Butzer U, et al. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. Anticancer Res. 2000;20:3259-3264.
18. Raymond E, Lawrence R, Izbicka E, et al. Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res. 1998;4:1021-1029.
19. Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol. 1998;25(suppl 5):4-12.
20. Culy CR, Clemett D, Wiseman LR. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs. 2000;60:895-924.
21. Maindrault-Goebel F, Louvet C, André T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-FU regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 6). Eur J Cancer. 1999;9:1338-1342.
22. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.
23. Louvet C, Andre T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol. 2002;20:4543-4548.
24. Ducreux M, Mitry E, Ould-Kaci M, et al. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol. 2004;15:467-473.
25. Fleming TR. One-sample multiple testing procedures for phase II clinical trials. Biometrics. 1982;38:143-151.
26. Pederiva S, Caspar CB. Management of acute oxaliplatin-related peripheral sensory neuropathy with magnesium and calcium. Proc Am Soc Clin Oncol. 2005;Abstract 282.
27. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions. Clin Cancer Res. 2004;10(Pt 1):4055- 4061.
28. Louvet C, Andre T, Liedo G, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR Multicenter Phase II Study. J Clin Oncol. 2002;20:1512-1518.
29. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR AND GISCAD phase III trial. J Clin Oncol. 2005;23:3509-3516.
30. Stathopoulos G, Aravantinos G, Syrigos K, et al. A randomized Phase III study of irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer (Abstract). Proc Am Soc Clin Oncol. 2005;4106.
31. Heinemann V, Hoehler T, Seipelt G. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx): a randomized phase II trial in advanced pancreatic cancer (Abstract). Proc Am Soc Clin Oncol. 2005;4030.
32. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine versus gemcitabine alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Oncology Group (CECOG) (Abstract). Proc Am Soc Clin Oncol. 2005; 4010.
33. Cunningham D, et al. Phase III randomized comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. ECCO 13, Abstract PS11, presented Nov. 2, 2005.